Loading...
Market
Units of FluMist nasal spray vaccine sold by end of 2024 flu season?
2
Resolution / Starting Odds
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
More than 2 million • 25%
Sales data released by AstraZeneca or third-party pharmacy reports
Story
FDA Approves First At-Home FluMist for Self- or Caregiver-Administration
Sep 20, 2024, 06:34 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray vaccine for self- or caregiver-administration, making it the first influenza vaccine that can be administered at home without the need for a healthcare provider. The vaccine is approved for individuals aged 2 through 49 years and aims to expand consumer access to medicines, reduce costs, and lower barriers to care. This approval represents a significant step in broadening vaccination options and enhancing public health measures. Interested individuals will complete a screening and eligibility assessment through a third-party pharmacy.
View original story
Similar markets
Yes • 50%
No • 50%
1 to 2 million • 25%
Less than 1 million • 25%
2 to 3 million • 25%
More than 3 million • 25%
Yes • 50%
No • 50%
Less than 100,000 units • 25%
100,000 to 500,000 units • 25%
500,000 to 1 million units • 25%
More than 1 million units • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Yes • 50%
No • 50%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
Yes • 50%
No • 50%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%